10-K · February 27, 2026
Amneal reported fiscal 2025 revenue of approximately $3.019 billion (quarters summed) with Q4 revenue of $814.3M (vs. est. $810.7M) and continued margin stability (gross ~36.9%). The company is executing a strategy…
Earnings analysis · 10-Q
AMRX earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Amneal Pharmaceuticals reported Q1 2026 earnings with a revenue of $722.5 million and an EPS of $0.19, both exceeding analyst expectations. The results show a 3.9% revenue growth year-over-year, driven by gains in the…
Read full summary
Amneal Pharmaceuticals reported Q1 2026 earnings with a revenue of $722.5 million and an EPS of $0.19, both exceeding analyst expectations. The results show a 3.9% revenue growth year-over-year, driven by gains in the Specialty segment, although one segment saw a revenue decline. Guidance for FY 2026 remains optimistic with anticipated revenue between $3.05 billion and $3.15 billion and adjusted EPS of $0.95 to $1.05.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.19
- Segment
- Affordable Medicines
- Segment
- Specialty
- Segment
- AvKARE
What stood out
-
Revenue Increased Year-Over-Year
Net revenue for Q1 2026 was $722.5 million, up 3.9% from $695.4 million in Q1 2025.
-
Strong EPS Performance
Reported EPS of $0.19, exceeding the estimate of $0.17.
-
Specialty Segment Growth
Specialty revenue rose 23.1% to $133.3 million, largely due to increased sales of CREXONT® and BREKIYA®.
-
Reduced Cost of Goods Sold
Cost of goods sold decreased 8.4% year-over-year, contributing to a gross margin increase to 44.3%.
-
Affirmed FY 2026 Guidance
Maintains revenue guidance of $3.05B to $3.15B and EPS guidance of $0.95 to $1.05.
What to watch
-
Pending Acquisition of Kashiv
The acquisition may not be completed on schedule or at all, potentially impacting future growth.
-
Increased Litigation Costs
$35.9 million paid in litigation settlements related to the Nationwide Opioids Settlement Agreement in Q1 2026.
-
Foreign Trade Tariffs Risks
Changes in trade policies and tariffs may increase costs or disrupt supply chains.
Management's outlook
Affirmed previously announced increased guidance for FY 2026.
Earlier filings 4
10-Q · November 6, 2025
Amneal reported quarterly revenue of $784,513,000 (up $82,045,000 vs. $702,468,000 a year ago) with gross profit of $273,974,000 but compressed gross margin to 34.9% (from 38.4% prior year). Operating income declined to…
10-Q · August 7, 2025
Amneal reported Q2 net revenue of $724,508,000, up $22,728,000 (+3.2%) versus Q2 2024, with gross profit rising to $286,253,000 and gross margin expanding to 39.5% from 35.6%. Operating income improved to $111,372,000…
10-Q · August 9, 2024
Amneal Pharmaceuticals reported strong growth in Q2 2024, with revenues of $701.78 million, up 17.3% from the previous quarter and 17.3% year-over-year. However, despite the revenue increase, the net income was $5.99…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.